ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) Operating cash flow 2016–2024
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$73.2MFY2024 · since FY2016: -$48.2M → -$73.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$73.2M | +48.0% |
| FY2023 | -$140.9M | +0.6% |
| FY2022 | -$141.8M | -1421.4% |
| FY2021 | $10.7M | +120.0% |
| FY2020 | -$53.6M | +52.4% |
| FY2019 | -$112.5M | -7.8% |
| FY2018 | -$104.4M | -92.2% |
| FY2017 | -$54.3M | -12.8% |
| FY2016 | -$48.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ADAPY financial trends
ADAPY RevenueADAPY Net incomeADAPY Net marginADAPY Gross profitADAPY Gross marginADAPY Operating incomeADAPY Operating marginADAPY Free cash flowADAPY Capital expendituresADAPY Return on equityADAPY Stock buybacksADAPY Dividends paidADAPY Total assetsADAPY Total liabilitiesADAPY Shareholders’ equityADAPY overview →